Oncology

Hartwig and Ultima Genomics Collaborate to Reduce Costs for Whole Genome Cancer Profiling, Minimal Residual Disease Testing and Generating Genetic Data at Scale

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Medical Devices, Health, Genetics, Oncology, Database, Genetic testing, Disease, Patient, NGS, Research, Cancer, Ultima, Architecture, MRD, Medical foundation, Hartwig, Blood, SNV, Medical imaging

This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.

Key Points: 
  • This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.
  • In parallel, platform strengths will be explored for minimal residual disease detection in blood of cancer patients with a one-size-fits-all solution that builds on pre-existing complete tumor profile information.
  • “Collaborating with Hartwig to deploy our technology toward whole genome cancer profiling, MRD testing and generating genomic information at scale is an exciting milestone,” said Gilad Almogy, CEO of Ultima Genomics.
  • Furthermore, lower costs can enable Hartwig to affordably create genetic datasets at national population scale to improve cancer research and ultimately outcomes for future patients.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Survival, A-DNA, Patient, Neoplasm, DNA, Biology, AACR, Clinical trial, Skin, Medical imaging

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers.
  • “Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
  • BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models.

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Colorectal cancer, Cetuximab, Progression-free survival, Patient, FACP, Bristol Myers Squibb, University, MD Anderson Cancer Center, AACR, Pacific Time Zone, CRC, FDA, PDUFA, Pharmaceutical industry

The data will also be published simultaneously in Cancer Discovery .

Key Points: 
  • The data will also be published simultaneously in Cancer Discovery .
  • The safety profile for KRAZATI plus cetuximab was manageable and consistent with previous reports, and with the known safety profile of each drug individually.
  • In previous studies, treatment with cetuximab as a single agent did not offer a clinical benefit in patients with KRAS-mutated colorectal cancer.
  • KRAZATI is a registered trademark of Mirati Therapeutics, Inc., a Bristol Myers Squibb company.

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Sunday, April 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, TP53, Patient, Lung, Arginine, AACR, Cholangiocarcinoma, Therapy, TRAC, Pancreas, CRISPR, TCR, Vaccine

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • “We are also proud to present preclinical data from our cell therapy targeting KRAS G12D, which highlights the promising potential of our proprietary non-viral knock-in THRIVE™ platform.
  • The study supports the planned clinical investigation of the novel KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy in 2024.
  • These data support the planned clinical development of a novel non-viral TRAC-knocked-in T cell therapy for the treatment of p53 R175H-mutant solid tumors.

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Retrieved on: 
Sunday, April 7, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, SOC, Melanoma Research, Oncogene, RNA-binding protein, Patient, SVP, Neoplasm, RNA, Cancer, Messenger, Melanoma, Lung cancer, Society, IND, Immortalised cell line, AACR, Breast cancer, RBP, Therapy, Translational medicine, Vaccine

These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .

Key Points: 
  • These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
  • eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
  • Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
  • “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.

Early is Good Announces Collaboration with Mayo Clinic to Develop a Comprehensive Liquid Biopsy Test for Men with Advanced Prostate Cancer

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Medical Devices, Health, Consumer, Men, Biotechnology, EIG, Prostate cancer, Disease, Education, Patient, Mayo Clinic, Research, Death, Cancer, Liquid biopsy, Integration platform, Pharmaceutical industry

Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.

Key Points: 
  • Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.
  • This collaboration to develop a comprehensive multi-omic test aims to significantly improve patient outcomes for men with advanced prostate cancer," says Thakshila Liyanage, Ph.D., Founder & CEO of Early is Good.
  • This novel liquid biopsy test seeks to enable comprehensive care plans for men with mCRPC.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

OVARIAN CANCER RESEARCH ALLIANCE LAUNCHES INNOVATIVE "FIND A DOCTOR" TOOL TO EMPOWER PATIENTS NATIONWIDE

Retrieved on: 
Tuesday, April 9, 2024
Komodo, Diagnosis, Ovarian cancer, Database, Patient, Research, Oncology, Oncology nursing, Ovary, OCRA, Clinical trial, Geography, Ovarian Cancer Research Alliance, Physician, Birth control

NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Ovarian Cancer Research Alliance (OCRA) proudly unveiled its latest innovation in supporting individuals affected by ovarian and other gynecologic cancers: the "Find a Doctor" tool.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Ovarian Cancer Research Alliance (OCRA) proudly unveiled its latest innovation in supporting individuals affected by ovarian and other gynecologic cancers: the "Find a Doctor" tool.
  • Navigating a diagnosis of ovarian or other gynecologic cancer can be overwhelming, and finding the right medical team is paramount to ensuring the best possible outcomes.
  • "Access to quality care is a critical issue of equity for patients," said Audra Moran, President and CEO of OCRA.
  • The new tool underscores OCRA's ongoing commitment to advancing research, raising awareness, and providing support to the ovarian cancer community.

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on: 
Monday, April 8, 2024
Clinical research, Stanford Cancer Institute, Hematology, Oncology, Associate, Caregiver, Colorectal cancer, Education, Chairperson, Patient, FACP, Research, NCCN, University, Cancer, Glomus tumor, Fox Chase Cancer Center, Leukemia, MBA, FRCP, MPH, Drug development, Health, Management

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
  • He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • "As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
  • "I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
Thursday, March 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.